BioSpace News Archive

AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that LYNPARZA has been approved in the European Union .

Consistent with its requirements under Regulation FD, Castellum, Inc. (NYSE-American: CTM) provides the following information from CEO Mark Fuller for its shareholders, prospective shareholders, and other stakeholders.

Chemomab Therapeutics, Ltd. today announced that an independent Data Monitoring Committee (DMC) has completed a safety review of the company’s ongoing Phase 2 trial of lead product CM-101 in primary sclerosing cholangitis (PSC) patients.

REGENXBIO Inc. (Nasdaq: RGNX) today announced a comprehensive program update to outline its progress and development plans for RGX-181 and RGX-381.

Ad hoc announcement pursuant to Art. 53 LR – Achiko AG is pleased to provide updates on test performance, production and sales.

Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,459,328 covering the mesylate salt formulation of cytisinicline and the process for its development.

Sutro Biopharma, Inc. today announced it will host a conference call and webcast to present data from its Phase 1 dose-expansion trial and a registrational path forward for STRO-002.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to Health Canada to initiate a Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic targeting ketohexokinase.

Moleculin Biotech, Inc. today announced it has received approval from the Agenzia Italiana del Farmaco and the Istituto Superiore di Sanità for its Phase 1/2 trial evaluating Annamycin in combination with Cytarabine (Ara-C) in the treatment of subjects with AML who are refractory to or relapsed after induction therapy (MB-106).

Teladoc Health , Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced today that Jason Gorevic, chief executive officer, and Mala Murthy, chief financial officer, will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 9, 2023.